Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05833984
Other study ID # IMM01-04
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 17, 2022
Est. completion date November 20, 2024

Study information

Verified date April 2023
Source ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Contact Zhenzhen Zong
Phone 86-21-38016387
Email zhenzhen.zong@immuneonco.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, multicenter, phase 1b/2 trial of IMM01 (SIRPĪ± Fc) plus tislelizumab in patients with advanced solid tumors and lymphomas.


Description:

This open-label, multicenter, phase 1b/2 trial is conducted to evaluate the safety, tolerability and preliminary activity in patients with advanced solid tumors and lymphomas. This trial includes two parts: the phase 1b dose escalation part and the phase 2 dose expansion part. In the dose escalation part with a standard 3+3 design, IMM01 (1.0, 1.5, 2.0 mg/kg) was administered once a week and tislelizumab (200mg) was administered once every 3 weeks. In the dose expansion part, IMM01 (the dose determined in the dose escalation part) was administered once a week and tislelizumab (200mg) was administered once every 3 weeks. And the cohorts includes HNSCC, NSCLC, SCLC, R/R cHL and others.


Recruitment information / eligibility

Status Recruiting
Enrollment 309
Est. completion date November 20, 2024
Est. primary completion date February 7, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years old, male or female 2. Life expectancy=12 weeks; 3. Phase 1b: Patients with advanced solid tumors diagnosed by histology or cytology, who have been failure to previous standard treatments; Phase 2: Patients with HNSCC, NPC, OC, NSCLC, SCLC, HCC, cHL and other solid tumors diagnosed by histology or cytology, who have been failure to first-line standard treatment (including PD-1/L1) at least; 4. ECOG PS of 0 or 1; 5. Adequate organs function, including bone marrow, hepatic, renal, cardiac, coagulation. 6. Adverse events associated with previous anti-tumor therapy have returned to= grade 1(NCI CTCAE V5.0); Exclusion Criteria: 1. Previous treatment with CD47 inhibitor/SIRPainhibitor or fusion protein; 2. Patients with symptomatic or progressive central nervous system (CNS) metastasis; 3. Uncontrolled hypertension, pulmonary hypertension or unstable angina, myocardial infarction within 6 months prior to administration; a history of chronic heart failure (NYHA G3/4); severe arrhythmia; 4. A history of arterial thrombosis, deep venous thrombosis and pulmonary embolism within 3 months prior to administration; 5. A history of moderate or severe dyspnea, interstitial lung disease (ILD) or servre pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency; 6. With other malignant tumors; 7. Diseases that may cause gastrointestinal bleeding or perforation; 8. Uncontrollable pleural, peritoneal or pericardial effusions; 9. A history of immunodeficiency; 10. A history of autoimmune diseases; 11. Uncontrolled severe active infections.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IMM01
IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.
Tislelizumab
Tislelizumab 200mg Q3W IV

Locations

Country Name City State
China Zhejiang Cancer Hospital Hangzhou
China Shandong Provincial Institute of Cancer Prevention and Treatment Jinan
China The Third Affiliated Hospital of Qiqihar Medical University Qiqihar
China Shanghai Chest Hospital Shanghai
China Henan Cancer Hospital Zhengzhou

Sponsors (1)

Lead Sponsor Collaborator
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity in dose escalation part DLT observation 21 days
Primary MTD/RP2D in dose escalation part DLT observation 21 days
Primary ORR in dose expansion part up to 12 months
Secondary TRAEs up to 12 months
Secondary PFS up to 12 months
Secondary DOR up to 12 months
Secondary DCR up to 12 months
Secondary Cmax up to 12 months
Secondary T1/2 up to 12 months
Secondary AUC up to 12 months
Secondary ADA up to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2